UBS cuts Brent crude oil forecasts
Director Kevin D Freeman acquired 5,000 shares of GALECTIN THERAPEUTICS INC (NASDAQ:GALT) on July 17, 2025, at a price of $2.899 per share, for a total transaction value of $14,495. The purchase comes amid strong momentum, with the stock up 15% in the past week and 133% over six months, though InvestingPro analysis indicates overbought conditions.
Following the transaction, Freeman directly owns 49,769 shares of common stock. He also indirectly owns 80,000 shares through a limited liability company, Freeman Global Holdings LLC, and 18,063 shares through an IRA. The $187 million market cap company maintains a FAIR financial health score, with its next earnings report due August 18, 2025. For deeper insider trading analysis and additional insights, check out InvestingPro, which offers 8 more key tips for GALT.
In other recent news, Galectin Therapeutics has secured a $10 million unsecured line of credit from its Board Chairman, Richard E. Uihlein. This credit facility, which can be accessed until April 2026, will help fund the company’s ongoing development of belapectin, its leading drug candidate for MASH cirrhosis and portal hypertension. The maturity dates for Uihlein’s existing $30 million in convertible notes and $81 million in previous credit lines have also been extended. Additionally, Galectin Therapeutics recently received a buy rating from H.C. Wainwright, which set a price target of $6.00, citing belapectin as a promising therapy in development. The NAVIGATE trial, a study on belapectin, showed positive results, indicating a significant reduction in the incidence of new varices in patients with MASH cirrhosis. The safety profile of belapectin was comparable to placebo, with a lower incidence of liver stiffness progression. These findings were presented at the European Association for the Study of the Liver Congress in Amsterdam. Galectin Therapeutics plans to present further data to the FDA and is seeking partnerships for belapectin’s development and commercialization.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.